| European contribution to the study of ROS: A summary of the findings and prospects for the future from the COST action BM1203 (EU-ROS) J Egea, I Fabregat, YM Frapart, P Ghezzi, A Görlach, T Kietzmann, ... Redox biology 13, 94-162, 2017 | 338 | 2017 |
| Redox control of protein degradation M Pajares, N Jiménez-Moreno, IHK Dias, B Debelec, M Vucetic, ... Redox biology 6, 409-420, 2015 | 185 | 2015 |
| The redox biology network in cancer pathophysiology and therapeutics G Manda, G Isvoranu, MV Comanescu, A Manea, BD Butuner, ... Redox biology 5, 347-357, 2015 | 140 | 2015 |
| Detection of 8-OHdG as a diagnostic biomarker KS Korkmaz, BD Butuner, D Roggenbuck Journal of Laboratory and Precision Medicine 3, 2018 | 74 | 2018 |
| Inflammation‐mediated abrogation of androgen signaling: an in vitro model of prostate cell inflammation B Debelec‐Butuner, C Alapinar, L Varisli, B Erbaykent‐Tepedelen, ... Molecular carcinogenesis 53 (2), 85-97, 2014 | 65 | 2014 |
| Development of EphA2 siRNA-loaded lipid nanoparticles and combination with a small‐molecule histone demethylase inhibitor in prostate cancer cells and tumor spheroids E Oner, M Kotmakci, AM Baird, SG Gray, B Debelec Butuner, E Bozkurt, ... Journal of nanobiotechnology 19, 1-20, 2021 | 48 | 2021 |
| Ubiquitously expressed hematological and neurological expressed 1 downregulates Akt-mediated GSK3β signaling, and its knockdown results in deregulated G2/M transition in … L Varisli, C Gonen-Korkmaz, B Debelec-Butuner, B Erbaykent-Tepedelen, ... DNA and cell biology 30 (6), 419-429, 2011 | 43 | 2011 |
| TNFα-mediated loss of β-catenin/E-cadherin association and subsequent increase in cell migration is partially restored by NKX3. 1 expression in prostate cells B Debelec-Butuner, C Alapinar, N Ertunc, C Gonen-Korkmaz, ... PloS one 9 (10), e109868, 2014 | 41 | 2014 |
| Androgen regulated HN1 leads proteosomal degradation of androgen receptor (AR) and negatively influences AR mediated transactivation in prostate cells L Varisli, C Gonen-Korkmaz, HM Syed, N Bogurcu, B Debelec-Butuner, ... Molecular and cellular endocrinology 350 (1), 107-117, 2012 | 38 | 2012 |
| HOXB13 contributes to G1/S and G2/M checkpoint controls in prostate SM Hamid, S Cicek, S Karamil, MB Ozturk, B Debelec-Butuner, ... Molecular and cellular endocrinology 383 (1-2), 38-47, 2014 | 34 | 2014 |
| Design, synthesis, and in vitro biological evaluation of novel thiazolopyrimidine derivatives as antileishmanial compounds H Istanbullu, G Bayraktar, H Akbaba, I Cavus, G Coban, ... Archiv der Pharmazie 353 (8), 1900325, 2020 | 27 | 2020 |
| Inflammation contributes to NKX3. 1 loss and augments DNA damage but does not alter the DNA damage response via increased SIRT1 expression B Debelec-Butuner, N Ertunc, KS Korkmaz Journal of inflammation 12, 1-9, 2015 | 25 | 2015 |
| Mutant telomeric repeats in yeast can disrupt the negative regulation of recombination-mediated telomere maintenance and create an alternative lengthening of telomeres-like … LH Bechard, BD Butuner, GJ Peterson, W McRae, Z Topcu, ... Molecular and cellular biology, 2009 | 23 | 2009 |
| European contribution to the study of ROS: a summary of the findings and prospects for the future from the COST action BM1203 (EU-ROS). Redox Biol 13: 94–162 J Egea, I Fabregat, YM Frapart, P Ghezzi, A Görlach, T Kietzmann, ... | 13 | 2017 |
| NKX3. 1 contributes to S phase entry and regulates DNA damage response (DDR) in prostate cancer cell lines B Erbaykent-Tepedelen, B Özmen, L Varisli, C Gonen-Korkmaz, ... Biochemical and biophysical research communications 414 (1), 123-128, 2011 | 13 | 2011 |
| Nutlin3a-loaded nanoparticles show enhanced apoptotic activity on prostate cancer cells B Debelec-Butuner, M Kotmakci, E Oner, G Ozduman, AG Kantarci Molecular biotechnology 61, 489-497, 2019 | 11 | 2019 |
| EGE VE AKDENİZ BÖLGESİ'NDE ÜROPATOJEN ESCHERICHIA COLI KÖKENLERİNİN FLOROKİNOLONLARA DUYARLILIĞI B DEBELEÇ, G COŞAR İnfeksiyon Derg (Turkish J Infect 21 (1), 15-21, 2007 | 10 | 2007 |
| Oxidative DNA damage-mediated genomic heterogeneity is regulated by NKX3. 1 in prostate cancer B Debelec-Butuner, A Bostancı, F Ozcan, O Singin, S Karamil, M Aslan, ... Cancer Investigation 37 (2), 113-126, 2019 | 9 | 2019 |
| Design, synthesis, in vitro–In vivo biological evaluation of novel thiazolopyrimidine compounds as antileishmanial agent with PTR1 inhibition H Istanbullu, G Bayraktar, G Karakaya, H Akbaba, NE Perk, I Cavus, ... European Journal of Medicinal Chemistry 247, 115049, 2023 | 8 | 2023 |
| Ferutinin content and cytotoxic effects of various Ferula L. species on prostate cancer (PC-3) cell line S Baykan, F Aydogan, MB Ozturk, B Debelec-Butuner, Ç Yengin, B Ozturk J. Res. Pharm 24, 142-149, 2020 | 8 | 2020 |
